SML2561
ML162
≥98% (HPLC), glutathione peroxidase inhibitor, powder
别名:
α-[（2-氯乙酰基）（3-氯-4-甲氧基苯基）氨基]-N-（2-苯乙基）-2-噻吩乙酰胺, 2-氯-N-（3-氯-4-甲氧基苯基）-N-（2-氧代-2-（苯乙基氨基）-1-（噻吩-2-基）乙基）乙酰胺, BRD-5421, BRD5421, CID 3689413, ML 162, ML-162, 分子库162
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C23H22Cl2N2O3S
化学文摘社编号:
分子量:
477.40
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
产品名称
ML162, ≥98% (HPLC)
SMILES string
[s]1c(ccc1)C(N(c3cc(c(cc3)OC)Cl)C(=O)CCl)C(=O)NCCc2ccccc2
InChI
1S/C23H22Cl2N2O3S/c1-30-19-10-9-17(14-18(19)25)27(21(28)15-24)22(20-8-5-13-31-20)23(29)26-12-11-16-6-3-2-4-7-16/h2-10,13-14,22H,11-12,15H2,1H3,(H,26,29)
InChI key
UNVKYJSNMVDZJE-UHFFFAOYSA-N
assay
≥98% (HPLC)
form
powder
color
white to very dark brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
ML162是一种小分子，可通过共价抑制细胞磷脂谷胱甘肽过氧化物酶（GPx-4；GPx4；GSHPx-4；PHGPx；SNGPx；snPHGPx）诱导铁死亡。癌症培养物中的合成致死性研究确定了诸如HRas（G12V）表达和富马酸水合酶（FH）缺失对ML162敏感性的影响因子（在BJeLR-HRas（G12V）&UOK262-FH-/-培养物中IC50分别为25 nM & 35 nM）。
共价磷脂谷胱甘肽过氧化物酶（GPx4；GSHPx-4；PHGPx；SNGPx；snPHGPx）抑制剂，可诱导铁死亡。
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Vasanthi S Viswanathan et al.
Nature, 547(7664), 453-457 (2017-07-06)
Plasticity of the cell state has been proposed to drive resistance to multiple classes of cancer therapies, thereby limiting their effectiveness. A high-mesenchymal cell state observed in human tumours and cancer cell lines has been associated with resistance to multiple
Emilie Logie et al.
International journal of molecular sciences, 22(22) (2021-11-28)
Disease relapse and therapy resistance remain key challenges in treating multiple myeloma. Underlying (epi-)mutational events can promote myelomagenesis and contribute to multi-drug and apoptosis resistance. Therefore, compounds inducing ferroptosis, a form of iron and lipid peroxidation-regulated cell death, are appealing
Michel Weïwer et al.
Bioorganic & medicinal chemistry letters, 22(4), 1822-1826 (2012-02-03)
Synthetic lethal screening is a chemical biology approach to identify small molecules that selectively kill oncogene-expressing cell lines with the goal of identifying pathways that provide specific targets against cancer cells. We performed a high-throughput screen of 303,282 compounds from
Amrita Basu et al.
Cell, 154(5), 1151-1161 (2013-09-03)
The high rate of clinical response to protein-kinase-targeting drugs matched to cancer patients with specific genomic alterations has prompted efforts to use cancer cell line (CCL) profiling to identify additional biomarkers of small-molecule sensitivities. We have quantitatively measured the sensitivity
Kenichi Shimada et al.
Cell chemical biology, 23(2), 225-235 (2016-02-09)
Precision medicine in oncology requires not only identification of cancer-associated mutations but also effective drugs for each cancer genotype, which is still a largely unsolved problem. One approach for the latter challenge has been large-scale testing of small molecules in
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持